Updated Results of TCAR Surveillance Project Presented at 2019 VEITHsymposium

NEW YORK, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the VEITHsymposium. In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project contemporaneously comparing TCAR to the surgical standard of care, carotid endarterectomy (CEA).

​Read More: https://www.globenewswire.com/news-release/2019/11/22/1951528/0/en/Favorable-Outcomes-with-TCAR-vs-Carotid-Endarterectomy-in-Patients-with-Carotid-Artery-Disease.html

BCBS of Minnesota inks deal with Omada to provide Type 2 diabetes tool to members

Digital chronic care platform Omada is deepening its relationship with Blue Cross and Blue Shield of Minnesota (Blue Cross), inking a new deal that provides the insurer’s commercial plan members access to the startup’s Type 2 diabetes care platform.

As part of yesterday’s news, Blue Cross also announced it would be making a strategic investment in Omada; however, the actual value of this investment was not disclosed. 

Omada’s Type 2 Diabetes Digital Care program includes a combination of digital resources and a human diabetes coach. The tool also connects participants to peer networks and weekly interactive sessions.  

Read More: https://www.mobihealthnews.com/news/north-america/bcbs-minnesota-inks-deal-omada-provide-type-2-diabetes-tool-members

Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference

Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on
the formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Donald Notman,
Chief Financial Officer of Ocular Therapeutix, will give a company
presentation on Thursday, November 21^st at 8:40 a.m. GMT at the Jefferies
2019 London Healthcare Conference being held at the Waldorf Hilton in London,
UK.

Read More: https://www.businesswire.com/news/home/20191114005159/en/

First New Device Trial Completed for Home Hemodialysis In 15 Years

SAN JOSE, Calif., Nov. 7, 2019 /PRNewswire/ -- Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing, global, dialysis market today announced publication of a multicenter, prospective, open-label study in Hemodialysis International.  Titled "Safety and Efficacy of the Tablo Hemodialysis System for In-center and In-home hemodialysis," the 30-patient study met both the safety and efficacy endpoints.  Tablo is currently FDA-cleared for use in hospitals and clinics and is under evaluation by FDA for use in the home.

​Over 21 consecutive weeks, patients went through four treatment periods in which hemodialysis was prescribed four times weekly:  one-week Run-In; eight-week In-Center; four-week Transition; eight-week In-Home.  The data showed a mean weekly standard Kt/V ≥ 2.8 for participants during the In-Center and In-Home treatment periods (compared to the trial endpoint of a standard Kt/V ≥ 2.1) and delivered ultrafiltration (UF) within 10% of prescribed UF.  There were no device-related pre-specified adverse events throughout the trial.  All patients who started the home arm with Tablo completed it, resulting in a 0% home arm drop-out rate.  

Read More: https://www.prnewswire.com/news-releases/results-from-prospective-multicenter-trial-evaluating-the-use-of-the-tablo-hemodialysis-system-for-home-dialysis-released-at-the-american-society-of-nephrology-scientific-meeting-300954040.html?tc=eml_cleartime